• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

MorphoSys (Group)

MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 29 are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys's antibody technology to receive regulatory approval. The Company's most advanced proprietary product candidate, MOR208, has been granted U.S. FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has approximately 320 employees. *

 

	Start	1992-01-01 established
	Today	MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
	Predecessor	Max Planck Society for the Advancement of Science
	Industry	biopharmaceutical
	Person	Kress, Jean-Paul (MorphoSys 201909– CEO before Syntimmune + Biogen + Sanofi Genzyme)
	Person 2	Holstein, Jens (MorphoSys 201105– CFO before Regional CFO Fresenius Kabi + Managing Director Fresenius Kabi Deutschland)
	Region	Martinsried
	Country	Germany
	Street	7 Semmelweisstr.
	City	82152 Planegg
	Tel	+49-89-89927-0
		Address record changed: 2018-07-24
Basic data	Employees	D: 101 to 500 (2017-12-31)
	Currency	EUR
	Annual sales	76,442,505 (revenues, consolidated (2018) 2018-12-31)
	Profit	-56,172,121 (2018-12-31)
	Cash	45,459,836 (2018-12-31)
		* Document for �About Section�: MorphoSys AG. (1/31/19). "Press Release: MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genmab". Planegg.
		Record changed: 2019-06-25

Advertisement

More documents for MorphoSys (Group)

• [1] MorphoSys AG. (11/20/19). "Press Release: Markus Enzelberger, Chief Scientific Officer of MorphoSys, Announces His Departure". Planegg....
• [2] MorphoSys AG. (11/15/19). "Press Release: MorphoSys Continues to Build Commercial Presence by Opening New U.S. Headoffice". Planegg & Boston, MA....
• [3] MorphoSys AG. (10/28/19). "Press Release: MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility". Planegg & Mechelen....
• [4] MorphoSys AG. (10/14/19). "Press Release: MorphoSys and I-Mab Biopharma Announce IND Clearance to Initiate Clinical Trials of MOR202/TJ202 for the Treatment of Multiple Myeloma in Mainland China". Planegg & Shanghai....
• [5] MorphoSys AG. (9/16/19). "Press Release: MorphoSys's Licensee Janssen Submits Biologics License Application to U.S. FDA of Tremfya (Guselkumab) for Treatment of Adults with Active Psoriatic Arthritis". Planegg....
• [6] Vivoryon Therapeutics AG. (8/29/19). "Press Release: Vivoryon Therapeutics Reports Financial Results for H1 2019 and Corporate Update". Halle (Saale)....
• [7] MorphoSys AG. (7/8/19). "Press Release: MorphoSys and Vivoryon Therapeutics Enter Agreement on Small Molecule Inhibitors of CD47-SIRP alpha Signaling in Immuno-Oncology". Planegg & Halle (Saale)....
• [8] MorphoSys AG. (7/3/19). "Press Release: MorphoSys' Licensing Partner GSK Initiates Phase 3 Clinical Program With Otilimab (MOR103/GSK3196165) in Rheumatoid Arthritis; MorphoSys Updates its Financial Guidance for 2019". Planegg....
• [9] GlaxoSmithKline plc. (7/3/19). "Press Release: GSK Announces Phase III Start for Its anti GM-CSF Antibody, Otilimab, in Patients with Rheumatoid Arthritis (RA)". London....
• [10] MorphoSys AG. (6/24/19). "Press Release: MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer". Planegg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.